<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 26, 1995
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey 1-10432 22-2429994
- ---------------- ------------ ----------------
(State of other (Commission (I.R.S. Employer
jurisdiction File Number) Identification
of incorporation Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
- 2 -
Item 5. Other Events
------------
On June 26, 1995, a shareholders' class action suit was
instituted in the United States District Court for the District of New Jersey
against Roberts Pharmaceutical Corporation ("Roberts" or the "Company") and
certain of its officers by Dieter Zander on behalf of all persons who purchased
shares of the Company's common stock between November 7, 1994 and May 31, 1995.
In his complaint, the plaintiff asserts claims against the Company and certain
of its officers for violations of Section 10(b) and 20(a) of the Securities and
Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder with
respect to press releases and filings with the Securities and Exchange
Commission and certain public statements allegedly made by the Company and
certain of its officers relating to its business. The plaintiff seeks to recover
damages in an unspecified amount. Roberts believes that it has complied with all
of its obligations under the federal securities laws. Accordingly, the Company
intends to defend vigorously against the plaintiff's allegations and considers
such allegations to be without merit.
<PAGE>
- 3 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: July 5, 1995 By: /s/ Anthony A. Rascio
----------------------------------
Anthony A. Rascio
Vice President
